Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN3 | Q9UGI6 | 3/20 | 0.64 |
| ▸ | CDK7 | P50613 | 12/20 | 0.49 |
| ▸ | CDK2 | P24941 | 8/20 | 0.47 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.47 |
| ▸ | CCNH | P51946 | 6/20 | 0.47 |
| ▸ | CDK1 | P06493 | 5/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.47 |
| ▸ | CDK9 | P50750 | 4/20 | 0.47 |
| ▸ | CDK4 | P11802 | 3/20 | 0.47 |
| ▸ | CDK8 | P49336 | 3/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.47 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CCND1 | P24385 | 2/20 | 0.47 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.47 |
| ▸ | INSRR | P14616 | 1/20 | 0.47 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26697064 | 0.88 | KCNN3 (0.50) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL26696755 | 0.88 | KCNN3 (0.51) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL30716174 | 0.88 | GSK3B (0.53) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL26696735 | 0.86 | KCNN3 (0.49) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL26696928 | 0.85 | KCNN3 (0.48) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL1370667 | 0.83 | CDK7 (0.66) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL26696833 | 0.83 | CDK2 (0.43) | KCNN3CDK2CCNE1CDK9CDK5 | |
| SCHEMBL23713368 | 0.83 | CDK2 (0.54) | KCNN3CDK7CDK2CCNE1CCNH | |
| SCHEMBL26696756 | 0.83 | KCNN3 (0.64) | KCNN3MAPK1MEN1MAPTKMT2A | |
| SCHEMBL19896576 | 0.82 | KCNN3 (0.45) | KCNN3MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024175024-A1 | NEW FUSED HETEROCYCLIC COMPOUND AS CDKS INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| WO-2024125532-A1 | NOVEL HETEROCYCLIC COMPOUND ACTING AS CDKS INHIBITOR, AND USE THEREOF | 杭州德睿智药科技有限公司 | 2024-06-20 | — | — | WO | disclosed |
| WO-2023227125-A1 | NEW FUSED-HETEROCYCLIC COMPOUND AS CDK INHIBITOR AND USE THEREOF | 杭州德睿智药科技有限公司 | 2023-11-30 | — | — | WO | disclosed |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-09-08 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2021-11-30 | — | — | US | disclosed |
| EP-3268000-B1 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECH LTD (IN) | 2021-08-04 | — | — | EP | disclosed |
| US-20180258092-A9 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-09-13 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-01 | — | — | US | disclosed |
| EP-3268000-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | Aurigene Discovery Technologies Limited (IN) | 2018-01-17 | — | — | EP | disclosed |
| WO-2016142855-A2 | PYRAZOLO[1,5-A][1,3,5]TRIAZINE AND PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES AS CDK INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057497-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885CDK7 11/4885CDK2 13/4885 |
| US-20220281871-A1 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK13, CDK1 | KCNN3 2555/4885CDK7 15/4885CDK2 16/4885 |
| US-11186576-B2 | Pyrazolo[1,5-A][1,3,5]triazine and pyrazolo[1,5-A]pyrimidine derivatives as CDK inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885CDK7 11/4885CDK2 13/4885 |
| US-20180258092-A9 | Pyrazolo[1,5-A][1,3,5]Triazine and Pyrazolo[1,5-A]Pyrimidine Derivatives as CDK Inhibitors | CDK15, CDK1, CDK19 | KCNN3 2255/4885CDK7 11/4885CDK2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.